Literature DB >> 1434853

Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970.

H Gharib1, W M McConahey, R D Tiegs, E J Bergstralh, J R Goellner, C S Grant, J A van Heerden, G W Sizemore, I D Hay.   

Abstract

We retrospectively reviewed the medical records of 65 consecutive patients with medullary thyroid carcinoma, who had had their primary surgical treatment at the Mayo Clinic during the years 1946 through 1970. Of these patients, 58 had sporadic and 7 had familial medullary thyroid carcinoma. Thyroid nodules were the most common initial manifestation. Near-total thyroidectomy was the most frequent initial operation. Survival was affected by the following factors: male sex, familial inheritance, size of the tumor, stage of the tumor (American Joint Committee on Cancer), and completeness of initial resection of the tumor. The mean duration of follow-up was 23.5 years, and the maximal follow-up was 36 years. Among 52 patients without initial distant metastatic involvement and with complete resection of the tumor, 20-year survival free of distant metastatic lesions was 81%. Overall 10- and 20-year survival rates were 63% and 44%, respectively. Because of the substantial morbidity and mortality associated with medullary thyroid carcinoma, early diagnosis and thorough initial resection of the tumor are important.

Entities:  

Mesh:

Year:  1992        PMID: 1434853     DOI: 10.1016/s0025-6196(12)60923-9

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  26 in total

1.  Prognostic factors for sporadic medullary thyroid carcinoma.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Mustafa Boyabatli
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

2.  Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival.

Authors:  Isabel Peixoto Callejo; José Américo Brito; Carlos Manuel Zagalo; Jorge Rosa Santos
Journal:  Clin Transl Oncol       Date:  2006-06       Impact factor: 3.405

3.  Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study.

Authors:  G Papi; S M Corsello; K Cioni; A M Pizzini; S Corrado; C Carapezzi; G Fadda; A Baldini; C Carani; A Pontecorvi; E Roti
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

Review 4.  Advances in the follow-up of differentiated or medullary thyroid cancer.

Authors:  Rossella Elisei; Aldo Pinchera
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

5.  MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.

Authors:  Caterina Mian; Gianmaria Pennelli; Matteo Fassan; Mariangela Balistreri; Susi Barollo; Elisabetta Cavedon; Francesca Galuppini; Marco Pizzi; Federica Vianello; Maria Rosa Pelizzo; Maria Elisa Girelli; Massimo Rugge; Giuseppe Opocher
Journal:  Thyroid       Date:  2012-06-29       Impact factor: 6.568

6.  Medullary thyroid carcinoma in Northern Ireland, 1967-1997.

Authors:  S J Dolan; C F Russell
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

7.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

8.  Markov model-based estimation of individual survival probability for medullary thyroid cancer patients.

Authors:  Olga Esik; Gábor Tusnády; Lajos Trón; András Boér; Zoltán Szentirmay; István Szabolcs; Károly Rácz; Erzsébet Lengyel; Judit Székely; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

9.  Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?

Authors:  Per Bümming; Håkan Ahlman; Bengt Nilsson; Ola Nilsson; Bo Wängberg; Svante Jansson
Journal:  Langenbecks Arch Surg       Date:  2008-07-15       Impact factor: 3.445

Review 10.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.